Company intelligence
As of June 17, 2026, Triveni Bio has raised at least $65M in equity across 1 sourced funding round.
Triveni Bio develops genetics-informed antibody and bispecific therapeutics for immunological and inflammatory diseases.
Is something wrong on this page?
Triveni Bio is a biotech company, based in Waltham, Massachusetts, USA, founded 2023.
| Date | Round | Amount | Valuation | Lead investors | Source |
|---|---|---|---|---|---|
| Jun 17, 2026 | Series C | $65M | — | — | Triveni Bio |
Equity only. “Equity raised” above sums the rounds with a dated, linked source; rumored rounds, tender offers and secondary sales are listed but not counted, and debt financing is listed separately.
Triveni Bio raised $65 million, co-led by Ascenta Capital and Janus Henderson Investors, to advance antibody-based therapeutics for immunological and inflammatory diseases. The round is a reminder that biotech capital is still flowing to differentiated science even in an AI-dominated market.
Triveni Bio raised $65 million co-led by Ascenta Capital and Janus Henderson to advance antibody-based therapeutics targeting immunological diseases. The round is part of a biotech rebound that's running alongside the AI-infrastructure boom rather than being crowded out by it.
Triveni Bio has raised at least $65M in equity across 1 sourced funding round tracked by Value Add VC. The most recent was a $65M Series C in June 2026, reported by Triveni Bio. Debt financing, tender offers and secondary sales are not counted.
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.
